Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies

Featuring:

Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, Oracle

Kenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc. 

***

We are excited to share the first episode in the fourth season (!) of Commercializing Living Therapies with CCRM. A big thanks to all our listeners.

In this episode, we explore how artificial intelligence (AI) and robotics are shaping the biomanufacturing facility of the future. Our guests discuss the technologies behind automation, including robotics, AI and machine learning, and how they play a role in development and manufacturing facilities for cell and gene therapies. They also cover the impact of these technologies on resolving challenges, like production bottlenecks, cost management and consistent quality control. As well, they illuminate how these technologies can affect both patients and clinicians. 

The episode concludes by highlighting some key considerations, including the importance of implementing change management activities as biomanufacturers bring both their organizations and customers along as their facilities evolve, as well as the need to upskill and reskill talent, and to collaborate with experts, to support scalability. 

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

CCRM received the 2025 William Edmond Logan Award for excellence in science communications for this podcast and its award-winning blog, Signals.